COMPARATIVE EVALUATION OF 3MIXTATIN WITH MTA AND FORMOCRESOL FOR PULPOTOMY OF PRIMARY MOLARS: AN IN-VIVO STUDY
Abstract
Background- Preservation of pulp vitality is of utmost importance to the normal physiological functioning of tooth in situ and physiological process of exfoliation in a tooth affected by disease or trauma. Pulpotomy serves such a purpose using various medicaments applied directly on vital pulp.
Aim- To compare and evaluate the clinical and radiographic success of 3Mixtatin with MTA and formocresol for pulpotomy of primary molars.
Materials & Methodology- Sixty primary molars were selected from 100 children aged between 5-9 years age who reported to Department of Pedodontics and Preventive Dentistry. All selected primary teeth were randomly divided in to three groups with 20 each depending on the type of pulpotomy medicament (Group I - Formocresol, Group II - MTA, Group III -3mixtatin) used. The children were then examined clinically and radiographically at 6 and 12 months.
Results & Observation- Overall clinical and radiographic success rate of three groups at 6 months and 12 months were Group I showed success rate of 91.7 percent ,81.7 percent Group II showed 100percent, 91.7percent Group III showed 95 percent,85 percent respectively.
Conclusion- 3mixtatin can be considered as additional pulpotomy medicament in primary teeth because of its bio-compatible and bioinductive properties.
Keywords
How to Cite This Article
N. Venugopal Reddy, Gladys Crystal Erpula, V. Daneswari, M. Ajay Reddy, Sadhana Jukanti and Varalaxmi G. (2024); COMPARATIVE EVALUATION OF 3MIXTATIN WITH MTA AND FORMOCRESOL FOR PULPOTOMY OF PRIMARY MOLARS: AN IN-VIVO STUDY, International Journal of Advanced Research (IJAR), 12 (06), 1498-1504, ISSN 2320-5407. DOI: https://doi.org/10.21474/IJAR01/19014
Corresponding Author
Publication Achievement
Publication video
🎉 Proud to contribute to scientific research! Share your publication with your colleagues and professional network.
Article Analytics
This work is licensed under a Creative Commons Attribution 4.0 International License.





